Recent News

• 09.12.2025 - Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
• 09.10.2025 - Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
• 08.21.2025 - Quantum BioPharma Announces Corporate Updates
• 08.11.2025 - Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
• 08.08.2025 - Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
• 08.07.2025 - Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Recent Filings

• 09.12.2025 - EX-99.1 EX-99.1
• 09.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.10.2025 - EX-99.1 EX-99.1
• 09.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.04.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.21.2025 - EX-99.1 EX-99.1
• 08.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.08.2025 - EX-99.1 EX-99.1